These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1258 related items for PubMed ID: 22528743

  • 1. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P, Gentile G, Angeli F, Reboldi G.
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ, Smith SM, Choksi R.
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A, Divchev D, Luchtefeld M, Schieffer B.
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [Abstract] [Full Text] [Related]

  • 6. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
    Verdecchia P, Angeli F, Cavallini C, Gattobigio R, Gentile G, Staessen JA, Reboldi G.
    Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
    [Abstract] [Full Text] [Related]

  • 7. Renin inhibition--benefit beyond hypertension control.
    Kher V.
    J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
    [Abstract] [Full Text] [Related]

  • 8. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K, Miller NH.
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [Abstract] [Full Text] [Related]

  • 9. Renin-angiotensin system blocking drugs.
    Robles NR, Cerezo I, Hernandez-Gallego R.
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):14-33. PubMed ID: 24038019
    [Abstract] [Full Text] [Related]

  • 10. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE, Julius S.
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [Abstract] [Full Text] [Related]

  • 11. [The future of renin inhibition].
    Uresin AY, Baran E.
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [Abstract] [Full Text] [Related]

  • 12. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandhara N, Hathiwala S, Smith E.
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [Abstract] [Full Text] [Related]

  • 13. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
    Petrella R, Michailidis P.
    Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
    [Abstract] [Full Text] [Related]

  • 14. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease.
    Mizuno Y, Jacob RF, Mason RP.
    Am J Hypertens; 2008 Oct; 21(10):1076-85. PubMed ID: 18756260
    [Abstract] [Full Text] [Related]

  • 15. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
    Lebel M, Rodrigue ME, Agharazii M, Larivière R.
    Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
    [Abstract] [Full Text] [Related]

  • 16. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM, Schmieder RE.
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [Abstract] [Full Text] [Related]

  • 17. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
    Tocci G, Sciarretta S, Facciolo C, Volpe M.
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):767-76. PubMed ID: 17605654
    [Abstract] [Full Text] [Related]

  • 18. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?
    Volpe M, Ruilope LM, McInnes GT, Waeber B, Weber MA.
    J Hum Hypertens; 2005 May; 19(5):331-9. PubMed ID: 15744333
    [Abstract] [Full Text] [Related]

  • 20. Management of cardiovascular risk with RAS inhibitor/CCB combination therapy.
    Dahlöf B.
    J Hum Hypertens; 2009 Feb; 23(2):77-85. PubMed ID: 18685606
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.